< Back to previous page
Project
A randomized phase II clinical trial in NSCLC combining SBRT and I.V. anti-PD-1 with or without I.T. anti-CTLA-4/anti-PD-L1 plus CD1c+ myDC (FWOTBM3)
We propose to perform a randomized phase II clinical trial in patients with oligometastatic non-small-cell lung cancer (NSCLC). NSCLC patients are eligible for this clinical trial when failed to respond or progress on anti-PD-1 therapy (pembrolizumab, with or without cytotoxic chemotherapy).
Date:1 Oct 2019 → 30 Sep 2023
Keywords:NSCLC
Disciplines:Clinical trials
Project type:Collaboration project